Aquarius Surgical Technologies Inc.
AQQRF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.04 | 0.04 | 0.00 |
| FCF Yield | -229.85% | -163.92% | 7.89% | -80.91% |
| EV / EBITDA | -7.96 | -9.52 | -7.85 | -1.24 |
| Quality | ||||
| ROIC | -78.33% | 82.32% | 190.78% | -2,516.01% |
| Gross Margin | 51.87% | 64.73% | 36.38% | 24.18% |
| Cash Conversion Ratio | 0.33 | 0.33 | -0.07 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -23.50% | -14.44% | -29.58% | -30.08% |
| Free Cash Flow Growth | -49.18% | -584.62% | 138.47% | 72.92% |
| Safety | ||||
| Net Debt / EBITDA | -7.76 | -9.15 | -6.55 | -0.98 |
| Interest Coverage | -1.80 | -1.59 | -2.94 | -3.23 |
| Efficiency | ||||
| Inventory Turnover | 2.19 | 4.08 | 2.97 | 5.58 |
| Cash Conversion Cycle | -10,051.20 | -430.53 | -231.25 | -1,112.27 |